1. A Novel Stilbene-Like Compound That Reduces Melanin through Inhibiting Melanocyte Differentiation and Proliferation without Inhibiting Tyrosinase
- Author
-
Noah A. Stueven, Aaron Monte, Kristy Martinson, and Cheng-chen Huang
- Subjects
0301 basic medicine ,MAPK/ERK pathway ,Aging ,melanocyte ,Tyrosinase ,proliferation ,Pharmaceutical Science ,Dermatology ,Melanocyte ,tyrosinase ,lcsh:Chemistry ,Melanin ,03 medical and health sciences ,0302 clinical medicine ,Melanocyte differentiation ,medicine ,Chemical Engineering (miscellaneous) ,Protein kinase A ,Protein kinase B ,Zebrafish ,biology ,Chemistry ,differentiation ,biology.organism_classification ,zebrafish ,Cell biology ,030104 developmental biology ,medicine.anatomical_structure ,lcsh:QD1-999 ,030220 oncology & carcinogenesis ,skin-lightening ,Surgery - Abstract
Cosmetic practices that use skin-lightening agents to obtain desired skin tones or treat pigment abnormalities have been popular worldwide. However, the molecular and cellular mechanisms of these agents are still largely unknown. Here we identified a family of compounds, with the lead compound named A11, that exhibited strong pigment reduction in developing zebrafish embryos. The pigment inhibition lasted for several days and is effective both before and after melanogenesis. By comparison with several known skin-lightening compounds, A11 appeared to be more potent and caused slower pigment recovery after withdrawal. A11, however, did not inhibit tyrosinase or cause apoptosis in melanocytes. We further found that A11 suppressed proliferation in melanocytes and reduced the number of differentiated melanocytes by activating MAPK (mitogen-activated protein kinase) and Akt. Finally, A11 also caused melanin reduction in mammalian melanocytes. Together, A11 might be a potent skin-lightening agent with novel mechanisms.
- Published
- 2018
- Full Text
- View/download PDF